Project Grant 2310453
Award Date
1/15/24
Completion Date
12/31/24
Dollars Obligated
$275K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Boulder, CO, USA
Similar Awards
The National Science Foundation awarded Ancilia, Inc. a $255,717 Small Business Technology Transfer Phase I Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The grant will support development of phage-resistant bacterial therapeutics from July 2021 through June 2023. The NSF Technology, Innovation, and Partnerships program seeks to advance science, engineering, and technology innovation to address national challenges. Under this award, Ancilia...
This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase II Cooperative Agreement award of $984,381 to Cobio Diagnostics Inc. aims to expand a new diagnostic technology for rapid, direct-from-specimen identification and antimicrobial susceptibility testing of major bloodborne bacterial pathogens, known as the "ESKAPE" pathogens. The project, funded under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, will develop and validate...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award for $305,000 provides funding to Giant Biosystems Inc., a small business located in Pasadena, CA, to develop a rapid antimicrobial susceptibility testing (AST) platform. The key products and services to be delivered through this award include:
Creation of a point-of-care AST kit that can provide results within 6-9 hours of sample collection, significantly faster than current...
This $305,000 SBIR Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a novel mammalian cell-based nano-biological coating for implantable medical devices. The project aims to create a biocompatible and antimicrobial coating to inhibit biofilm formation and protect against bacterial infections, including antibiotic-resistant strains, on orthopedic implants. Key technical objectives include...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) grant for $275,000 aims to develop new bacterial strains capable of efficiently producing difficult-to-express proteins through precision fermentation. The project seeks to engineer improved bacterial hosts to manufacture proteins used in detergents, personal care products, and dairy, enabling the production of these products with lower environmental...
This $275,000 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant awarded to Informuta, Inc. in New Orleans, LA aims to develop a platform for detecting genetic antibiotic resistance markers that can predict current and future susceptibility to therapeutics. The project will leverage next-generation sequencing techniques to identify mutational signatures in bacterial DNA that are indicative of past antibiotic exposure and predictive of rapid...
This $275,000 SBIR Phase I Project Grant, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop a generalized process to formulate and stabilize beneficial microbes for widespread adoption. The project, conducted by Seia Bio Inc., seeks to address the challenge of microbial stability when exposed to stressors such as heat, UV light, shock, and humidity. The proposed R&D will advance the understanding...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 to Resonantia Diagnostics, Inc. aims to develop a transformative diagnostic platform capable of rapidly identifying pathogens and determining their antimicrobial susceptibility directly from patient samples. The project seeks to achieve three key technical objectives: (1) demonstrate accurate antimicrobial susceptibility testing at low pathogen loads, (2) validate...
This $273,652 STTR Phase I Project Grant awarded by the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) to Phage Refinery LLC aims to develop a rapid and efficient predictive model for determining the persistence of bacteriophages as an alternative to traditional antibiotic treatments. The project will collect physical parameters and in-vivo persistence data for 400 phages in mouse models to create a statistical model that can estimate phage...
Felix Biotechnology Inc. received a $256,000 Small Business Innovation Research Phase I Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program. The 12-month project aims to leverage machine learning techniques to enable generalized phage therapy for pulmonary infections. Phage therapy utilizes bacteriophages, or viruses that infect bacteria, as an alternative to traditional antibiotics. This award will support Felix Biotechnology's...